Bio-Techne Corporation logo
TECHBio-Techne Corporation

Debt to Equity Ratio: 0.14

Is the debt to equity ratio high or low?

The debt to equity ratio of 0.14 is 34% below its 5-year average of 0.21, near the low end of its 5-year range (0.14–0.28).

As of Saturday, June 27, 2026. 27.16% below its 12-month average of 0.19.

Debt to Equity

TECH Debt to Equity Ratio

0.14

Reported quarterly debt to equity ratio; no daily interpolation.

-48.26% 5Y
TECH Debt to Equity Ratio

TECH Average Debt to Equity Ratio Chart

TECH Debt to Equity Ratio

TECH Current vs Average Debt to Equity Ratio Chart

TECH Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.14

DEBT TO EQUITY RATIO AVG TTM

0.19

DEBT TO EQUITY RATIO AVG 3Y

0.22

DEBT TO EQUITY RATIO AVG 5Y

0.21

DEBT TO EQUITY RATIO AVG 10Y

0.28

DEBT TO EQUITY RATIO AVG 15Y

0.21

DEBT TO EQUITY RATIO AVG 20Y

0.16

CURRENT VS TTM AVG

-27.16%

CURRENT VS 3Y AVG

-35.84%

CURRENT VS 5Y AVG

-34.34%

CURRENT VS 10Y AVG

-51.11%

CURRENT VS 15Y AVG

-33.95%

CURRENT VS 20Y AVG

-13.10%

TECH Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B0.140.190.220.21
Insulet Corp. (PODD)vs ›$10.86B0.690.931.711.82
Baxter International Inc. (BAX)vs ›$11.38B1.631.782.051.83
Molina Healthcare, Inc. (MOH)vs ›$11.79B0.970.830.760.84
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B3.232.451.881.68
Charles River Laboratories International, Inc. (CRL)vs ›$10.20B0.970.880.910.99
Tempus AI, Inc. (TEM)vs ›$9.80B2.705.515.515.51
Revvity, Inc. (RVTY)vs ›$12.61B0.480.450.510.56
Henry Schein, Inc. (HSIC)vs ›$9.61B1.140.990.790.64
Align Technology, Inc. (ALGN)vs ›$12.78B0.030.030.030.03

Financial Health

Debt/Equity

0.14

Current Ratio

3.46

Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Bio-Techne Corporation (TECH)?
The debt to equity ratio for TECH stock is 0.14.
Is Bio-Techne Corporation's debt to equity ratio high or low?
The debt to equity ratio of 0.14 is 34% below its 5-year average of 0.21, near the low end of its 5-year range (0.14–0.28).
What is the TTM average debt to equity ratio for Bio-Techne Corporation (TECH)?
The TTM average debt to equity ratio for TECH stock is 0.19.
What is the 3Y average debt to equity ratio for Bio-Techne Corporation (TECH)?
The 3Y average debt to equity ratio for TECH stock is 0.22.
What is the 5Y average debt to equity ratio for Bio-Techne Corporation (TECH)?
The 5Y average debt to equity ratio for TECH stock is 0.21.
What is the 10Y average debt to equity ratio for Bio-Techne Corporation (TECH)?
The 10Y average debt to equity ratio for TECH stock is 0.28.
What is the 15Y average debt to equity ratio for Bio-Techne Corporation (TECH)?
The 15Y average debt to equity ratio for TECH stock is 0.21.
What is the 20Y average debt to equity ratio for Bio-Techne Corporation (TECH)?
The 20Y average debt to equity ratio for TECH stock is 0.16.

TECH Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2026-03-310.14
2025-12-310.17
2025-09-300.20
2025-06-300.23
2025-03-310.21
2024-12-310.19
2024-09-300.19
2024-06-300.20
2024-03-310.25
2023-12-310.28
2023-09-300.28
2023-06-300.23
2023-03-310.25
2022-12-310.16
2022-09-300.20
2022-06-300.19
2022-03-310.19
2021-12-310.21
2021-09-300.23
2021-06-300.27
2021-03-310.19
2020-12-310.20
2020-09-300.28
2020-06-300.31
2020-03-310.39
2019-12-310.35
2019-09-300.48
2019-06-300.43
2019-03-310.46
2018-12-310.50
2018-09-300.51
2018-06-300.31
2018-03-310.37
2017-12-310.36
2017-09-300.35
2017-06-300.37
2017-03-310.39
2016-12-310.39
2016-09-300.42
2016-06-300.15
2016-03-310.19
2015-12-310.19
2015-09-300.20
2015-06-300.14
2015-03-310.23
2014-12-310.23
2014-09-300.16
2014-06-300.02
2014-03-310.00
2013-12-310.00
2013-09-300.00
2013-06-300.00
2013-03-310.01
2012-12-310.00
2012-09-300.00
2012-06-300.00
2012-03-310.00
2011-12-310.00
2011-09-300.00
2011-06-300.00
2011-03-310.00
2010-12-310.00
2010-09-300.00
2010-06-300.00
2010-03-310.00
2009-12-310.00
2009-09-300.00
2009-06-300.00
2009-03-310.00
2008-12-310.00
2008-09-300.00
2008-06-300.00
2008-03-310.00
2007-12-310.00
2007-09-300.00
2007-06-300.00
2007-03-310.00
2006-12-310.00
2006-09-300.04
2006-06-300.04
2006-03-310.04
2005-12-310.05
2005-09-300.05
2005-06-300.05
2005-03-310.06
2004-12-310.05
2004-09-300.05
2004-06-300.05
2004-03-310.06
2003-12-310.06
2003-09-300.07
2003-06-300.07
2003-03-310.08
2002-12-310.08
2002-09-300.08
2002-06-300.09

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman